Could ADHD Medications Treat Coexisting Depression and Anxiety? New Studies Say Yes.
August 26, 2026
ADHD medications decrease antidepressant usage and reduce symptoms of depression and anxiety in people diagnosed with attention deficit, suggest findings from three new studies.
Antidepressant and psychotropic medication use in adults often precedes an ADHD diagnosis; however, a new landmark study published in Acta Psychiatrica Scandinavica152 found that use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants decreased substantially after adults received an ADHD diagnosis and began treatment with a stimulant or non-stimulant medication.1
Women received antidepressant prescriptions prior to an ADHD diagnosis much more often than did men, according to the Finnish cohort study of 322,416 adults (66,146 with ADHD and 256,270 without). The researchers attribute this to clinicians misinterpreting or misdiagnosing ADHD symptoms as anxiety or depression in women. Depression and anxiety can also result from living with untreated ADHD. As many as 80% of adults with ADHD have at least one coexisting psychiatric disorder; the most common are generalized anxiety, social anxiety, and depression. 2
“ADHD is often associated with coexisting psychiatric conditions,” the researchers wrote. “Differential diagnosis between other conditions and ADHD is not always clear, and patients are sometimes initially treated for another disorder instead.”
Findings from the study support this: At the second-year follow-up, the use of SSRIs, benzodiazepine derivatives, diazepines, oxazepines, thiazepines and oxepines, and other antidepressants decreased in the ADHD cohort. However, SSRI and other antidepressant usage increased in the non-ADHD group during the same period.
Following an ADHD diagnosis, most patients were motivated to try ADHD medication: 95% of patients filled the prescribed medication; 80% of those bought the medication within 10 days. More than half of patients (56.5%) purchased extended-release methylphenidate (brand name: Ritalin).
Just one quarter of late-diagnosed adult patients with ADHD maintained continuous ADHD medication for five years or more.
“This indicates that ADHD drugs were not massively misused, as large purchases would be indicative of [abuse],” the researchers said. “Discontinuation may stem from symptom alleviation, adverse effects, or refinement of diagnoses.”
The study, which analyzed data from Finnish national registers between 2015 and 2020, also found that children and adolescents diagnosed later with ADHD used more antibiotics and anti-inflammatory drugs than did matched controls. After the children began ADHD treatment, the use of these drugs decreased more than it did in controls.
The researchers wrote that “future research is needed, for example, about possible anti-inflammatory effectiveness of ADHD medications, like that of selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors.”
While the Finnish study broadly evaluated how an ADHD diagnosis and subsequent treatment influences antidepressant usage, two new clinical trials took a deeper look into whether a single-medication approach could treat ADHD and co-occurring depression and/or anxiety.
Stimulant Treatment for Co-Occurring Anxiety
During an 8-week Phase 3b clinical trial, centanafadine (brand name: Simtriyo), a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system (CNS) stimulant, delivered statistically significant, clinically relevant improvements in both ADHD and anxiety symptoms.3 Centanafadine received FDA approval for the treatment of ADHD in adults and pediatric patients aged 6 years and older on July 24, 2026.
The trial included 315 adults, aged 18 to 65 years, with ADHD and coexisting generalized or social anxiety disorder. Study participants received either centanafadine XR 280mg or placebo once daily. The study analyzed symptom improvements using the Adult Investigator Symptom Rating Scale (AISRS) and the Hamilton Anxiety Rating Scale (HAM-A).
Non-Stimulant Treatment for Coexisting Depression and Anxiety
Another recent clinical trial published in The Journal of Clinical Psychiatry that adults with ADHD and coexisting depression and/or anxiety symptoms experienced substantial improvement in all three conditions while taking the non-stimulant viloxazine ER (brand name: Qelbree) extended-release capsules alone or in addition to existing treatments.4
During the open-label Phase 4 trial, 150 participants received 200mg of viloxazine ER once daily, with doses increasing up to 600mg. At week 14, the AISRS results showed improved ADHD symptoms and a significant reduction in total baseline AISRS scores. Depression and anxiety rating scales also showed significant improvement in symptoms from baseline to week 14: 71.8% of participants achieved a 30% reduction in AISRS total score, and half of the participants reduced their AISRS total score by 45.6%.
This was the first clinical trial of viloxazine ER in adults with ADHD to include participants with coexisting depression and/or anxiety and to allow concurrent medication use. In addition to viloxazine ER,
- 28.6% of participants used stimulant medications
- 44.7% of participants used antidepressants
- 14.9% of participants used anxiolytic and/or hypnotic medications
Viloxazine ER is an FDA-approved non-stimulant medication for children, ages 6 years or older, and adults with ADHD. 5 It is not approved as an antidepressant in the U.S. However, studies from the 1970s found viloxazine demonstrated antidepressant effects 6 In Europe, viloxazine was approved and used as an immediate-release drug for depression for approximately 30 years before being discontinued for commercial reasons unrelated to efficacy or safety. 7
Clinical Implications
More research is needed to determine whether ADHD medications effectively treat coexisting depression and/or anxiety or if symptom reduction is related to improvements in ADHD symptoms. However, one consistent takeaway from all these studies is the utility of ADHD medications.
The potential benefits of using one medication to treat both ADHD and coexisting depression and/or anxiety could improve safety and medication adherence issues for patients who already have executive function deficits.
“Simultaneous treatment of ADHD and depression and/or anxiety symptoms can be challenging, partly due to safety concerns about combining medications,” the authors of The Journal of Clinical Psychiatry article wrote.
Fewer prescription medications could also translate to greater cost savings for patients.
The steep out-of-pocket costs of ADHD care today — on average, more than $8,500 per child and $4,700 per adult annually — are driving families to ration medication, delay or skip medical appointments, and forgo interventions they rely on to function well, according to ADDitude’s Cost of ADHD Diagnosis & Treatment survey. Of the 1,970 survey respondents, 10% said their ADHD care costs exceeded 10% of their income.
“I just go without medication when I run short of money,” a respondent said.
“I never take my clinician-recommended dosage because I can’t afford it,” another survey respondent said.
“We are paying out-of-pocket for medication, so our kids don’t take it on weekends or vacations,” another mother commented.
“As with any treatment, the best approach to treating depression and/or anxiety and ADHD depends on the patient’s individual needs,” says Roberto Olivardia, Ph.D., who recommends clinicians consider both psychological and psychopharmacological treatments when treating patients with ADHD and coexisting anxiety and/or depression.
“Dealing with ADHD symptoms is challenging enough,” Olivardia says. “Dealing with depression or anxiety, too, is debilitating. Only with proper assessment and diagnosis can treatment for both, or either, be possible.”
Sources
1Westman, E., Prami, T., Kallio, A. et al. (2025). Use of antidepressants decreased after initiation of ADHD treatment in adults — a Finnish nationwide register study describing use of ADHD and non-ADHD medication in people with and without ADHD. Acta Psychiatrica Scandinavica152. https://doi.org/10.1111/acps.70007
2Katzman, M.A., Bilkey, T.S., Chokka, P.R., Fallu, A., & Klassen, L.J. (2017). Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. https://doi.org/10.1186/s12888-017-1463-3
3P3b short-term study of CTN in patients with ADHD and comorbid anxiety. ClinicalTrials.gov. May 6, 2026. Accessed July 1, 2026. https://clinicaltrials.gov/study/NCT06973577
4Adler, L.A., Lieberman, V.R., Brijbasi, L., Mattingly, G.W., et al. (2026). Viloxazine extended release in adults with attention-deficit/hyperactivity disorder and depression and/or anxiety symptoms: results from a decentralized, open-label, phase 4 trial. J Clin Psychiatry. https://doi.org/10.4088/JCP.25m16234
5Qelbree (viloxazine extended-release capsules). Prescribing information. In: Supernus Pharmaceuticals. Inc.; 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211964s013lbl.pdf
6Greenwood D. (1975). Animal pharmacology of viloxazine (Vivalan). J Int Med Res.
7Findling, R.L., Candler, S.A., Nasser, A.F., et al. (2021). Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. https://doi.org/10.1007/s40263-021-00825-w